Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Caribou Biosciences Inc., 3 years.
Caribou Biosciences Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 8, 2026 | Vaxcyte Inc. | Shares withheld for tax | −7,155 | $60.36 | $431,876 |
| Sep 2, 2026 | Vaxcyte Inc. | Shares withheld for tax | −1,432 | $61.58 | $88,183 |
| Aug 31, 2026 | Vaxcyte Inc. | Shares withheld for tax | −1,273 | $60.74 | $77,322 |
| Aug 3, 2026 | Vaxcyte Inc. | Option exercise | +10,000 | $5.35 | $53,500 |
| Aug 3, 2026 | Vaxcyte Inc. | Open-market sale | −6,956 | $53.76 | $373,955 |
| Aug 3, 2026 | Vaxcyte Inc. | Open-market sale | −3,044 | $54.18 | $164,924 |
| Jul 6, 2026 | Vaxcyte Inc. | Option exercise | +10,000 | $5.35 | $53,500 |
| Jul 6, 2026 | Vaxcyte Inc. | Open-market sale | −7,913 | $57.16 | $452,307 |
| Jul 6, 2026 | Vaxcyte Inc. | Open-market sale | −2,087 | $57.76 | $120,545 |
| Jun 18, 2026 | Vaxcyte Inc. | Option exercise | +10,000 | $5.35 | $53,500 |
| Jun 18, 2026 | Vaxcyte Inc. | Open-market sale | −10,000 | $53.00 | $530,000 |
| Mar 9, 2026 | Vaxcyte Inc. | Shares withheld for tax | −1,021 | $59.32 | $60,566 |
| Mar 2, 2026 | Vaxcyte Inc. | Shares withheld for tax | −1,009 | $61.98 | $62,538 |
| Feb 28, 2026 | Vaxcyte Inc. | Shares withheld for tax | −898 | $61.98 | $55,658 |
| Feb 26, 2026 | Vaxcyte Inc. | Grant or award | +44,864 | — | — |
Questions about Andrew Guggenhime
What boards is Andrew Guggenhime on?
Andrew Guggenhime sits on the board of Caribou Biosciences Inc.
How long has Andrew Guggenhime served on boards?
Our records show at least 4 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.